share_log

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.63%)

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.63%)

諾瓦瓦克斯醫藥 | SC 13G/A:超過5%持股股東披露文件(修正)-The Vanguard Group(9.63%)
美股SEC公告 ·  2024/11/04 10:24

Moomoo AI 已提取核心訊息

The Vanguard Group has filed an amendment to its Schedule 13G, indicating a change in its holdings of Novavax Inc common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 15,430,034 shares of Novavax, representing 9.63% of the company's class of common stock. The filing, made under Rule 13d-1(b) of the Securities Exchange Act of 1934, shows that The Vanguard Group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. This amendment reflects The Vanguard Group's position as a significant investor in Novavax, with the reported shares being held on behalf of its clients, including registered investment companies and other managed accounts.
The Vanguard Group has filed an amendment to its Schedule 13G, indicating a change in its holdings of Novavax Inc common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 15,430,034 shares of Novavax, representing 9.63% of the company's class of common stock. The filing, made under Rule 13d-1(b) of the Securities Exchange Act of 1934, shows that The Vanguard Group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. This amendment reflects The Vanguard Group's position as a significant investor in Novavax, with the reported shares being held on behalf of its clients, including registered investment companies and other managed accounts.
先鋒集團已向其第13G表格提交修正,表明其持有諾瓦瓦克斯醫藥公司普通股份額有所變動。截至2024年9月30日,先鋒集團報告持有諾瓦瓦克斯醫藥公司15,430,034股,佔公司普通股類的9.63%。根據1934年證券交易法規則13d-1(b)提交的申報顯示,先鋒集團對224,741股有共同表決權,並獨立行使對15,072,218股的決定權,另有357,816股的共同決定權。該修正反映出先鋒集團作爲諾瓦瓦克斯醫藥公司重要投資者的地位,報告的股份代表其客戶持有,包括註冊投資公司和其他管理帳戶。
先鋒集團已向其第13G表格提交修正,表明其持有諾瓦瓦克斯醫藥公司普通股份額有所變動。截至2024年9月30日,先鋒集團報告持有諾瓦瓦克斯醫藥公司15,430,034股,佔公司普通股類的9.63%。根據1934年證券交易法規則13d-1(b)提交的申報顯示,先鋒集團對224,741股有共同表決權,並獨立行使對15,072,218股的決定權,另有357,816股的共同決定權。該修正反映出先鋒集團作爲諾瓦瓦克斯醫藥公司重要投資者的地位,報告的股份代表其客戶持有,包括註冊投資公司和其他管理帳戶。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息